Prostate Cancer
A Phase 3, Randomized, Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)
- Details
ClinicalTrials.gov ID:
NCT06136650
Diagnosis Type:
NA
USOR Number:
- Address
,
P: